GET DAILY SIGNALSGlaukos (GKOS) Delivers Strong Q3 2026 Results with 58% Revenue Growth
Key Takeaways
- Third quarter 2026 net sales reached $211.0 million, up 58% year over year and above the roughly $168 million consensus estimate.
- Glaukos swung to GAAP net income of $2.0 million, or $0.03 per diluted share, compared with a loss of $16.2 million a year earlier.
- Adjusted (non-GAAP) diluted earnings per share came in at $0.47, sharply above the consensus expectation of a $0.10 loss.
- Management raised full-year 2026 revenue guidance to $775 million–$785 million and introduced preliminary 2027 sales guidance of about $1 billion.
- Growth was driven primarily by the iDose TR glaucoma implant and the newly launched Epioxa corneal therapy.
- For more on GKOS, explore dedicated pages on major news, today's price move, price targets, and forecasts.
Placing the Results in Context
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company focused on glaucoma, corneal disorders, and retinal diseases, entered this report with elevated expectations. The stock had already recovered sharply from its 52-week low and traded near record levels, meaning investors were looking for proof that its two growth engines could scale. The iDose TR implant has been lifting the U.S. glaucoma franchise, while Epioxa, launched commercially in March 2026, has been ramping through an expanding network of treatment sites. With the company still unprofitable on a GAAP basis in recent quarters, this report served as a key test of whether rapid revenue growth could finally translate into operating leverage and a clear path toward sustainable profitability. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The Quarter’s Reported Figures
Glaukos reported third quarter 2026 net sales of $211.0 million, a 58% increase from $133.5 million in the prior-year period and ahead of the consensus estimate of roughly $168 million. U.S. glaucoma revenue rose 47% to a record $118.6 million, while corneal health revenue jumped 154% to $59 million, reflecting the accelerating Epioxa launch. International glaucoma revenue increased 13.3% to about $33.4 million.
The company swung to GAAP net income of $2.0 million, or $0.03 per diluted share, from a loss of $16.2 million, or $0.28 per share, a year ago. On an adjusted (non-GAAP) basis, which excludes acquisition-related and other items, net income was $28.5 million, or $0.47 per diluted share — far exceeding the consensus forecast of a $0.10 loss and marking the company's first adjusted profit in eight quarters. GAAP gross margin expanded to roughly 85% from about 78% a year earlier.
Management raised its full-year 2026 revenue guidance to $775 million–$785 million, up from the prior range of $680 million–$700 million, and offered preliminary 2027 net sales guidance of approximately $1 billion.
Market Reaction and Investor Sentiment
Heading into the report, sentiment was cautiously optimistic but sensitive to valuation. Analysts widely rated the stock a strong buy, with the consensus price target implying modest upside from near-record levels, yet the shares had sold off more than 13% in early October following positive three-year Epioxa trial data amid valuation concerns. The third quarter's revenue beat, the swing to adjusted profitability, and the sharply raised guidance addressed the central question investors were asking: whether the growth story could convert into improving margins. The introduction of a $1 billion preliminary 2027 sales target provided a concrete forward milestone that had not previously been disclosed, reinforcing confidence in the durability of the iDose TR and Epioxa franchises.
Forward Outlook and Key Factors to Monitor
The raised full-year 2026 guidance and the new preliminary 2027 target of roughly $1 billion in net sales suggest management expects the current momentum to continue. Still, several factors will determine whether that trajectory holds. Reimbursement remains a key watchpoint: proposed Local Coverage Determinations affecting iDose TR, as well as potential physician fee reductions for cataract and MIGS procedures, could influence procedure volumes and pricing.
For Epioxa, the focus is on operational execution. The July 1, 2026 activation of its product-specific J-code, J2789, was an important step in streamlining reimbursement, and investors will monitor how quickly coverage pathways convert into treatment volume as the company expands toward sites covering more than 95% of the U.S. population.
Finally, cost discipline matters. Even as gross margins expand, selling, general, and administrative expenses have been rising with commercial buildout, and research and development spending remains elevated. Whether Glaukos can sustain its adjusted profitability while funding further launches will be central to how the market values the stock over the coming quarters.
Researching Comparable Opportunities
In my analysis of high-growth medical technology names like Glaukos, I often turn to Tickeron’s AI Screener. This AI-powered tool helps filter the market based on technical patterns, fundamentals, trends, volatility, and signals, allowing me to scan thousands of stocks and ETFs with customizable criteria such as industry, market cap, and performance metrics. It provides a structured way to identify comparable opportunities across sectors more efficiently.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
GKOS's RSI Oscillator recovers from oversold territory
The RSI Indicator for GKOS moved out of oversold territory on September 28, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 18 similar instances when the indicator left oversold territory. In 16 of the 18 cases the stock moved higher. This puts the odds of a move higher at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on GKOS as a result. In 79 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for GKOS just turned positive on October 02, 2026. Looking at past instances where GKOS's MACD turned positive, the stock continued to rise in 48 of 58 cases over the following month. The odds of a continued upward trend are 83%.
GKOS moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for GKOS crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.
Following a +5.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where GKOS advanced for three days, in 248 of 317 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GKOS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
GKOS broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GKOS entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 29 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. GKOS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.658) is normal, around the industry mean (3.837). P/E Ratio (-55.404) is within average values for comparable stocks, (2.078). Projected Growth (PEG Ratio) (12.570) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (15.456) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an ophthalmic medical device company
Industry MedicalNursingServices
Advertisement